Hipertrofik kardiyomiyopatili hastaların risk sınıflandırmasında görüntüleme yöntemlerinin yeri

Hipertrofik kardiyomiyopati (HKM) genetik geçişli bir kalp hastalığıdır. Genç sporcularda ani kardiyak ölümün (AKÖ) en sık nedenidir. Bu ölümlerin önlenebilmesi için hekimler büyük özen göstermektedir. Ani kardiyak ölüm açısından yüksek riskli hastalar implante edilebilen kardiyoverter defibrilatör tedavisi için adaydırlar. Ani kardiyak ölüm açısından yüksek riskli bu bireylerin saptanabilmesi için yapılan risk sınıflandırmasında kardiyak görüntüleme yöntemleri önemli bilgiler sağlamaktadır. Görüntüleme yöntemleri ile elde edilen bilgilerin doğru yorumlanması ve önlemlerin alınması bu hastalar için hayat kurtarıcı olması nedeniyle büyük önem taşımaktadır. Teknolojideki gelişmeler yüksek riskli hastaların erken tespitine önemli katkılar sağlamaktadır. Bu derlemede biz HKM’li hastaların risk sınıflandırmasında görüntüleme yöntemlerinin yeri ve önemini değerlendirdik.

The role of cardiac imaging modalities in risk stratification of patients with hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder. It is the most common reason of sudden cardiac death (SCD) in young athletes. Prevention of these deaths is of high concern among physicians. Patients with high risk of SCD are canditates for implantable cardioverter device therapy. Cardiac imaging modalities provide important data in risk stratification for identifying HCM patients with high risk of SCD and interpreting the data obtained by different imaging modalities is important for prevention of SCD in this population. In this review, we evaluated the role of imaging modalities and their values in risk stratification of patients with HCM.

___

  • 1. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002;287(10):1308-20.
  • 2. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54(3):201-11.
  • 3. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;58(25):212-60.
  • 4. Maron BJ. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J 2010;74(11):2271-82.
  • 5. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006;113(14):1807-16.
  • 6. Doi YL, McKenna WJ, Oakley CM, et al. 'Pseudo' systolic anterior motion in patients with hypertensive heart disease. Eur Heart J 1983;4(12):838-45.
  • 7. Mun JB, Oh AR, Park HS, et al. The Unusual Suspect: Anemia-induced Systolic Anterior Motion of the Mitral Valve and Intraventricular Dynamic Obstruction in a Hyperdynamic Heart as Unexpected Causes of Exertional Dyspnea after Cardiac Surgery. Korean J Thorac Cardiovasc Surg 2013;46(6):457-60.
  • 8. Spirito P, Maron BJ, Chiarella F, et al. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: Relation to magnitude of left ventricular hypertrophy. Circulation 1985;72(2):310-6.
  • 9. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26(7):1699-708.
  • 10. Olszewski R, Timperley J, Szmigielski C, et al. The clinical applications of contrast echocardiography. Eur J Echocardiogr 2007;8(3):13-23.
  • 11. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342(24):1778-85.
  • 12. Maron MS, Hauser TH, Dubrow E, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol 2007;100(8):1293-8.
  • 13. Thaman R, Gimeno JR, Murphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 2005;91(7):920-5.
  • 14. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006;114(3):216-25.
  • 15. Panza JA, Petrone RK, Fananapazir L, et al. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;19(1):91-9.
  • 16. Maron BJ, McIntosh CL, Klues HG, et al. Morphologic basis for obstruction to right ventricular outflow in HCM. Am J Cardiol 1993;71(12):1089-94.
  • 17. Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99(2):254-61.
  • 18. Tülüce K, Tülüce SY, Yavuzgil O, et al. The left atrial phasic functions and the relationship with plasma N-terminal pro-B-type natriuretic peptide levels and symptomatic states in patients with hypertrophic cardiomyopathy. Anadolu Kardiyol Derg 2014;14(8):719-27.
  • 19. Kitaoka H, Kubo T, Okawa M, et al. Utility of tissue Doppler imaging to predict exercise capacity in hypertrophic cardiomyopathy: Comparison with B-type natriuretic peptide. J Cardiol 2009;53(3):361-7.
  • 20. Efthimiadis GK, Giannakoulas G, Parcharidou DG, et al. Clinical significance of tissue Doppler imaging in patients with hypertrophic cardiomyopathy. Circ J 2007;71(6):897-903.
  • 21. Nistri S, Olivotto I, Betocchi S, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006;98(7):960-5.
  • 22. Pritchett AM, Jacobsen SJ, Mahoney DW, et al. Left atrial volume as an index of left atrial size: A population-based study. J Am Coll Cardiol 2003;41(6):1036-43.
  • 23. Losi MA, Betocchi S, Barbati G, et al. Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009;22(1):76-81.
  • 24. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114(21):2232-9.
  • 25. Shah JS, Esteban MT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008;94(10):1288-94.
  • 26. Okeie K, Shimizu M, Yoshio H, et al. Left ventricular systolic dysfunction during exercise and dobutamine stres in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2000;36(3):856-63.
  • 27. Peteiro J, Bouzas-Mosquera A, Fernandez X, et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2012;25(2):182-9.
  • 28. Nagueh SF, Mahmarian JJ. Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;48(12):2410-22.
  • 29. Ganame J, Mertens L, Eidem BW, et al. Regional myocardial deformation in children with hypertrophiccardiomyopathy: morphological and clinical correlations. Eur Heart J 2007;28(23):2886-94.
  • 30. Carasso S, Yang H, Woo A, et al. Systolic myocardial mechanics in hypertrophic cardiomyopathy: Novel concepts and implications for clinical status. J Am Soc Echocardiogr 2008;21(6):675-83.
  • 31. Kato TS, Noda A, Izawa H, et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation 2004;110(25):3808-14.
  • 32. Paraskevaidis IA, Panou F, Papadopoulos C, et al. Evaluation of left atrial longitudinal function in patients with hypertrophic cardiomyopathy: a tissue Doppler imaging and two-dimensional strain study. Heart 2009;95(6):483-9.
  • 33. To ACY, Dhillon A, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy. JACC Cardiovasc Imag 2011;4(10):1123-37.
  • 34. Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: Correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 2009;54(3):242-9.
  • 35. O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56(11):867-74.
  • 36. Moon JC, Fisher NG, McKenna WJ, et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004;90(6):645-9.
  • 37. Pennell DJ. Ventricular volume and mass by CMR. J Cardiovasc Magn Reson 2002;4(4):507-13.
  • 38. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357(9254):420-4.
  • 39. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43(12):2260-4.
  • 40. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100(19):1992-2002.
  • 41. Hoey ETD, Gulati GS, Ganeshan A, et al. Cardiovascular MRI for assessment of infectious and inflammatory conditions of the heart. AJR Am J Roentgenol 2011;197(1):103-12.
  • 42. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51(14):1369-74.
  • 43. Fluechter S, Kuschyk J, Wolpert C, et al. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophiccardiomyopathy. J Cardiovasc Magn Reson 2010;12(1):30.
  • 44. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56(11):875-87.
  • 45. Maron MS, Appelbaum E, Harrigan CJ, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008;1(3):184-91.
  • 46. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010;121(3):445-56.
  • 47. Maron MS, Olivotto I, Harrigan C, et al. Mitral valveabnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011;124(1):40-7.
  • 48. Kwon DH, Setser RM, Thamilarasan M, et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 2008;94(10):1295-301.
  • 49. Harrigan CJ, Appelbaum E, Maron BJ, et al. Significance of papillarymuscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008;101(5):668-73.
  • 50. Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy: an emerging but under-recognized pathophysiologic mechanism. J Am Coll Cardiol 2009;54(9):866-75.
  • 51. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008;118(15):1541-9.
  • 52. Amano Y, Takayama M, Kumita S. Contrast-enhanced myocardial T1-weighted scout (Look-Locker) imaging for the detection of myocardial damages in hypertrophic cardiomyopathy. J Magn Reson Imaging 2009;30(4):778-84.
  • 53. Holloway CJ, Suttie J, Dass S, et al. Clinical cardiac magnetic resonance spectroscopy. Prog Cardiovasc Dis 2011;54(3):320-7.
  • 54. Austin BA, Popovic ZB, Kwon DH, et al. Aortic stiffness independently predicts exercise capacity in hypertrophic cardiomyopathy: a multimodality imaging study. Heart 2010;96(16):1303-10.
  • 55. O’Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987;76(6):1214-23.
  • 56. Dilsizian V, Bonow RO, Epstein SE, et al. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22(3):796-804.
  • 57. Nagueh SF, Mahmarian JJ. Noninvasive cardiac imaging in patients withhypertrophic cardiomyopathy. J Am Coll Cardiol 2006;48(12):2410-22.
  • 58. Camici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17(4):879-86.
  • 59. Zhao C, Shuke N, Okizaki A, et al. Comparison of myocardial fatty acid metabolism with left ventricular function and perfusion in cardiomyopathies by 123I-BMIPP SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT. Ann Nucl Med 2003;17(7):541-8.
  • 60. Terai H, Shimizu M, Ino H, et al. Changes in cardiac sympathetic nerve innervations and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy. J Nucl Med 2003;44(10):1612-7.
  • 61. Schafers M, Durka D, Rhodes CG, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998;82(1):57-62.
  • 62. Sipola P, Vanninen E, Aronen HJ, et al. Cardiac adrenergic activity is associated with left ventricular hypertrophyin genetically homogeneous subjects with hypertrophic cardiomyopathy. J Nucl Med 2003;44(4):487-93.
  • 63. Choudhury L, Guzzetti S, Lefroy DC, et al. Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart 1996;75(1):50-4.
  • 64. Orakzai SH, Orakzai RH, Nasir K, et al. Assessment of cardiac function using multidetector row computed tomography. J Comput Assist Tomogr 2006;30(4):555-63.
  • 65. Dewey M, Müller M, Eddicks S, et al. Evaluation of global and regional left ventricular function with 16-slice computed tomography, biplane cine ventriculography, and two dimensional transthoracic echocardiography: Comparison with magnetic resonance imaging. J Am Coll Cardiol 2006;48(10):2034-44.
  • 66. Mao SS, Budoff MJ, Oudiz RJ, et al. Effect of exercise on left and right ventricular ejection fraction and wall motion in patients with coronary artery disease: An electron beam computed tomography study. Int J Cardiol 1999;71(1):23-31.
  • 67. Gopal A, Mao SS, Karlsberg D, et al. Radiation reduction with prospective ECG-triggering acquisition using 64-multidetector computed tomographic angiography. Int J Cardiovasc Imaging 2009;25(4):405-16.
  • 68. Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2011;24(5):473-98.
Ege Tıp Dergisi-Cover
  • ISSN: 1016-9113
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1962
  • Yayıncı: Ersin HACIOĞLU
Sayıdaki Diğer Makaleler

Primary carcinoid tumor of the kidney

İbrahim GELİNCİK, Polat TÜRKER, ÖMER ÖZÇAĞLAYAN, Ramazan UYGUR

Risk factors for febrile neutropenic attacks in patients who were given chemotherapy treatment for hematological malignancies

Nur SOYER, ASU FERGÜN YILMAZ, MURAT TOMBULOĞLU, Ahmet DİRİCAN, SABİRE ŞÖHRET AYDEMİR, Seçkin ÇAĞIRAGAN, Ayhan DÖNMEZ

Öğretimsel videoların hemşirelik beceri eğitiminde kullanımı

Esra KORHAN AKIN, Çağlayan ÜSTÜN

Co-existence of celiac disease and eosinophilic esophagitis: Is it a coincidence for the two diseases?

YELİZ ÇAĞAN APPAK, SEMİN AYHAN, HASAN ERHUN KASIRGA

Fiziksel Tıp ve Rehabilitasyon polikliniğine başvuran hastalarda D vitamin düzeyi ile lipid profili ilişkisi

Asiye Mukaddes EROL, CANAN ÇELİK, Kadir HACIOĞLU, Didem İLDEMİR, Altuğ GÜNER, Aykut ÇELİK, Sezin SOLUM

Laboratuvar tasarımı bir HBV DNA kantitasyon protokolü rutin kullanıma uygun olabilir mi? – Ege Üniversitesi Klinik Viroloji Laboratuvarı deneyimi

Ajda TURHAN, İmre ALTUĞLU, Selda ERENSOY, Rüçhan SERTÖZ

Bir üniversite hastanesine başvuran gebe kadınlarda Toxoplasma gondii seroprevalansı

ŞENOL ŞENTÜRK, Mehmet KAĞITCI, Gülşah BALIK, Savaş ÖZDEMİR, KAZIM ŞAHİN

Bir olgu üzerinden gebelikte adneksiyel kitlelere yaklaşım

Mete URAL ÜLKÜ, YEŞİM BAYOĞLU TEKİN, Figen ŞAHİN KIR

Hipertrofik kardiyomiyopatili hastaların risk sınıflandırmasında görüntüleme yöntemlerinin yeri

Kamil TÜLÜCE, SADIK VOLKAN EMREN, Selcen TÜLÜCE YAKAR, Cemil GÜRGÜN, Cahide ÇINAR SOYDAŞ

Analysis of factors affecting long-term survival in surgically-treated second primary lung cancer patients with previous malignancy

AYŞE GÜL ERGÖNÜL, ALİ ÖZDİL, Kutsal TURHAN, TEVFİK İLKER AKÇAM, Alparslan ÇAKAN, Ufuk ÇAĞRICI